文献速递血栓与止血

组织因子途径抑制物对凝血的调控:对血友病治疗的启示

Regulation of coagulation by tissue factor pathway inhibitor: Implications for hemophilia therapy.
PubMed 文献 · J Thromb Haemost · 2022-03-27

组织因子途径抑制物(TFPI)是一种可变剪接的抗凝蛋白,主要在凝血酶生成前抑制凝血启动阶段。TFPIα和TFPIβ两种主要剪接异构体定位于血管内和周围不同部位,通过Kunitz结构域抑制FXa和TF-FVIIa,并影响细胞转运与信号通路。TFPIα与FV和蛋白S形成复合物循环,不依赖TF启动复合物抑制FXa并阻止活性凝血酶原酶形成。针对TFPI Kunitz 2结构域的抗体可阻断这种调控,被用作恢复血友病止血的治疗策略。

要点

  • TFPI主要在凝血酶生成前抑制凝血启动阶段,是血友病出血的重要调节因子。
  • TFPIα和TFPIβ通过Kunitz 2域抑制FXa、通过Kunitz 1域抑制TF-FVIIa。
  • TFPIα与FV和蛋白S形成复合物循环,不依赖TF启动复合物抑制FXa。

核心结论

  • TFPI通过抑制FXa和TF-FVIIa调控凝血启动,针对其Kunitz 2结构域的抗体可恢复血友病止血。

研究设计与样本

  • 综述,未报告检索范围。

主要发现

  • TFPI是一种可变剪接的抗凝蛋白,主要在凝血酶生成前抑制凝血启动阶段。
  • TFPIα和TFPIβ定位于血管内和周围不同部位,均通过Kunitz 2域直接抑制FXa、通过Kunitz 1域抑制TF-FVIIa。
  • TFPI通过形成定位于不同细胞微环境的复合物并结合其他细胞表面受体,改变TF通路凝血蛋白酶驱动的细胞转运和信号通路。
  • TFPIα与FV和蛋白S形成复合物循环,不依赖TF启动复合物抑制FXa并阻止活性凝血酶原酶形成。
  • 针对TFPI Kunitz 2结构域的抗体可有效阻断TFPI对凝血酶生成的调控,被用作恢复血友病止血的治疗。

临床怎么用

  • 针对TFPI Kunitz 2结构域的抗体被用作恢复血友病止血的治疗策略。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Tissue factor pathway inhibitor (TFPI) is an alternatively spliced anticoagulant protein that primarily dampens the initiation phase of coagulation before thrombin is generated. As such, TFPI's actions are localized to cells expressing TF and to sites of injury, where it is an important regulator of bleeding in hemophilia. The major splice isoforms TFPIα and TFPIβ localize to different sites within and surrounding the vasculature. Both forms directly inhibit factor Xa (FXa) via their Kunitz 2 domain and inhibit TF-FVIIa via their Kunitz 1 domain in a tight complex primarily localized to cells. By forming complexes localized to distinct cellular microenvironments and engaging additional cell surface receptors, TFPI alters cellular trafficking and signaling pathways driven by coagulation proteases of the TF pathway. TFPIα, which circulates in complex with FV and protein S, also serves an inhibitor of FXa independent of the TF initiation complex and prevents the formation of an active prothrombinase. This regulation of thrombin generation in the context of vessel injury is effectively blocked by antibodies to Kunitz 2 domain of TFPI and exploited as a therapy to restore efficient hemostasis in hemophilia.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Mast AE, Ruf W. Regulation of coagulation by tissue factor pathway inhibitor: Implications for hemophilia therapy. J Thromb Haemost. 2022. PMID: 35279938. doi:10.1111/jth.15697

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。